PMID- 22856635
OWN - NLM
STAT- MEDLINE
DCOM- 20121220
LR  - 20161020
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 33
IP  - 4
DP  - 2012 Jul-Aug
TI  - Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent 
      hereditary angioedema attacks.
PG  - 348-53
LID - 10.2500/aap.2012.33.3585 [doi]
AB  - Patients with hereditary angioedema (HAE) may have attacks triggered by dental, 
      medical, or surgical procedures. This analysis evaluated the efficacy and safety 
      of preprocedural administration of nanofiltered C1 esterase inhibitor (C1 INH-nf; 
      human) for the prevention of HAE attacks during and after dental, medical, or 
      surgical procedures. Data were reviewed retrospectively from two acute treatment 
      trials in which at least 1000 U of C1 INH-nf was administered i.v. within 24 
      hours before an emergency or noncosmetic medical, surgical, or dental procedure. 
      Dosing data, HAE attacks reported within 72 hours, and adverse events (AEs) 
      reported within 7 days after a preprocedural dose of C1 INH-nf were analyzed to 
      assess efficacy and safety. Forty-one unique subjects (8 children and 33 adults) 
      received C1 INH-nf for 91 procedures (40 in children and 51 in adults). The 
      majority of procedures (56%) involved dental work and 44% involved a variety of 
      surgical or medical procedures. A single 1000-U dose of C1 INH-nf was 
      administered for 96% of procedures. An HAE attack did not occur within 72 hours 
      after C1 INH-nf dosing for 98% (89/91) of procedures. Two HAE attacks were 
      reported after the procedure, and both were treated with C1 INH-nf and achieved 
      relief. None of the reported AEs were judged to be related to C1 INH-nf or were 
      associated with an HAE attack. This analysis supports the efficacy and safety of 
      preprocedural administration of C1 INH-nf for the prevention of HAE attacks.
FAU - Grant, J Andrew
AU  - Grant JA
AD  - Department of Internal Medicine, University of Texas Medical Branch, Galveston, 
      USA. jagrant@utmb.edu
FAU - White, Martha V
AU  - White MV
FAU - Li, H Henry
AU  - Li HH
FAU - Fitts, David
AU  - Fitts D
FAU - Kalfus, Ira N
AU  - Kalfus IN
FAU - Uknis, Marc E
AU  - Uknis ME
FAU - Lumry, William R
AU  - Lumry WR
LA  - eng
SI  - ClinicalTrials.gov/NCT00289211
SI  - ClinicalTrials.gov/NCT00438815
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Complement C1 Inhibitor Protein)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angioedemas, Hereditary/drug therapy/etiology/*prevention & control
MH  - Child
MH  - Complement C1 Inhibitor Protein/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Female
MH  - Filtration/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nanotechnology/methods
MH  - *Premedication
MH  - Surgical Procedures, Operative/*adverse effects
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/08/04 06:00
MHDA- 2012/12/21 06:00
CRDT- 2012/08/04 06:00
PHST- 2012/08/04 06:00 [entrez]
PHST- 2012/08/04 06:00 [pubmed]
PHST- 2012/12/21 06:00 [medline]
AID - 10.2500/aap.2012.33.3585 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2012 Jul-Aug;33(4):348-53. doi: 10.2500/aap.2012.33.3585.